TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35872697
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus intensive exercise diet therapy
Study: 36544634
Drug: ACP gel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACP gel
Study: 33745372
Drug: Neuroanimation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroanimation therapy (NAT)
Study: 33745372
Drug: Neuroanimation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroanimation therapy (NAT) and Conventional occupational therapy (COT) combined
Study: 35357753
Drug: 30% metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% metformin cream
Study: 35357753
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream (Kligman's formula)
Study: 34217079
Drug: Glyphosate 7.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyphosate 7.2 g a.e. ha−1 in winter season
Study: 34217079
Drug: Glyphosate 36.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyphosate 36.0 g a.e. ha−1 in winter season
Study: 34217079
Drug: Glyphosate 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyphosate 1.8 g a.e. ha−1 in winter season
Study: 34217079
Drug: Glyphosate 12
Normalized name: GLYPHOSATE
DrugBank: Glyphosate (DB04539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyphosate 12 g a.e. ha−1 in wet season
Study: 33734452
Drug: THY1773 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: THY1773 (10 mg/day to 110 mg/day)
Study: 33734452
Drug: THY1773 (TS-121
Approvals — FDA: no, EMA: no, PMDA: no
Description: THY1773 (TS-121 capsule)
Study: 33870705
Drug: Oral Anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Anticoagulation (OAC)
Study: 32772571
Drug: Antiplatelet Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet Therapy (APT)
Study: 2004897541
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (only regular therapy)
Study: 34538275
Drug: ACT-guided heparinization
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-guided heparinization (100 IU/kg bolus of heparin with ACT measurements)
Study: 34538275
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU of heparin (no ACT measurements)
Study: 36017827
Drug: RID-TDS (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: RID-TDS (twice weekly)
Study: 36017827
Drug: Exelon® (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exelon® (once daily)
Study: 32206785
Drug: Prolyl-hydroxylase domain
Normalized name: antihemophilic factor, porcine B-domain truncated recombinant Injection [Obizur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolyl-hydroxylase domain (PHD) inhibitors
Study: 33148203
Drug: Randomised controlled
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised controlled trial of first-line intravenous iron
Study: 32450733
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propofol and desflurane
Study: 33561968
Drug: Lacto-ovo-vegetarian diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacto-ovo-vegetarian diet (VD; 65 g/day protein)
Study: 33561968
Drug: Western-type diet
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western-type diet (WD; 95 g/day protein)
Study: 33561968
Drug: Mixed diet
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed diet (MD; 65 g/day protein)
Study: 35527114
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution combined with orthokeratology (OK)
Study: 35527114
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution with spectacles
Study: 32940765
Drug: Clotrimazole (CT)
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole (CT) 100 mg
Study: 32940765
Drug: Dequalinium chloride
Normalized name: dequalinium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dequalinium chloride (DQC) 10 mg
Study: 36217643
Drug: SmearOFF as
Approvals — FDA: no, EMA: no, PMDA: no
Description: SmearOFF as the final irrigant + 2% Chlorhexidine gel as intracanal medicament (n=14)
Study: 35652260
Drug: Letrozole (LZ)
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole (LZ) 5 mg
Study: 34976331
Drug: Active initiation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active initiation of secondary prevention therapy (aspirin, beta-blockers, statins, ACEI/ARBs)
Study: 34976331
Drug: Passive continuation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive continuation of prior medication (aspirin, beta-blockers, statins)
Study: 32652910
Drug: Non-drug users
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug users (N-MMT group)
Study: 35093230
Drug: Inactivated whole‐virion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated whole‐virion SARS‐CoV‐2 vaccine (CoronaVac)
Study: 34733813
Drug: Yoga group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga group (N = 49) attended a yoga course consisting of 10 sessions (1.5 h each) on a weekly basis
Study: 35427491
Drug: Hypothetical gonorrhoea
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical gonorrhoea vaccine
Study: 32243716
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of ketorolac tromethamine prior to local anaesthesia with 2% lignocaine and 1:80,000 adrenaline
Study: 32243716
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of ketorolac tromethamine prior to local anaesthesia with 4% articaine and 1:100,000 adrenaline
Study: 32888192
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion (CII) of enoxaparin
Study: 32888192
Drug: Standard subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard subcutaneous bolus (SCB) of enoxaparin
Study: 32216731
Drug: Pelvic intensity-modulated
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic intensity-modulated radiation therapy (IMRT)
Study: 36490309
Drug: metformin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin combined with neoadjuvant chemotherapy and trastuzumab
Study: 36490309
Drug: neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemotherapy and trastuzumab without metformin
Study: 32729631
Drug: Pimavanserin (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin (34 mg)
Study: 35273972
Drug: Alginate drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate drink (one bottle twice a day for 8 weeks after A-FMT)
Study: 32183874
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual, wait-list control group
Study: 33334157
Drug: Pathway 3
Normalized name: Immunoglobulin g1-lambda, anti-(human tissue factor pathway inhibitor (tfpi, extrinsic pathway inhibitor, epi, lipoprotein-associated coagulation inhibitor, laci))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pathway 3 (community mental health stepped care): CHWs screen patients and deliver behavioral EBIs in the community and refer medication management cases to PCPs in clinics.
Study: 33675081
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (70 g/280 kcal) drink
Study: 36760537
Drug: Radial Extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial Extracorporeal Shock Wave Therapy (ESWT) applied once a week for 5 weeks, combined with a 5-week advanced rehabilitation training program (30 minutes/session, 5 times/week) starting at 3 months postoperatively
Study: 33196155
Drug: Warfarin (dose-adjusted,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (dose-adjusted, target INR 2.0 to 3.0)
Study: 35781888
Drug: 3-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day antibiotic protocol (500 mg amoxicillin and metronidazole 3 times a day for 3 days, followed by placebo for 4 days)
Study: 35781888
Drug: 7-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day antibiotic protocol (500 mg amoxicillin and metronidazole 3 times a day for 7 days)
Study: 35485332
Drug: JNJ-64794964 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64794964 0.2 mg
Study: 35485332
Drug: JNJ-64794964 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64794964 0.6 mg
Study: 35485332
Drug: JNJ-64794964 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64794964 1.25 mg
Study: 35485332
Drug: JNJ-64794964 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64794964 1.8 mg
Study: 35485332
Drug: JNJ-64794964 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64794964 1.25 mg (MD phase)
Study: 35810356
Drug: rh‐bFGF nasal‐spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh‐bFGF nasal‐spray
Study: 35810356
Drug: rh‐bFGF nasal‐spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh‐bFGF nasal‐spray and drop
Study: 36335297
Drug: 100-μg dexmedetomidine
Normalized name: dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100-μg dexmedetomidine plus 35-mL 0.5% levobupivacaine
Study: 36335297
Drug: 50-μg dexmedetomidine
Normalized name: dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50-μg dexmedetomidine plus 35-mL 0.5% levobupivacaine
Study: 36335297
Drug: 35-mL 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35-mL 0.5% levobupivacaine plus normal saline
Study: 33991221
Drug: Intravaginal estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal estriol 0.03 mg plus Lactobacillus acidophilus 100 million viable cell vaginal tablets
Study: 32668323
Drug: LUS-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUS-guided treatment
Study: 33501671
Drug: Nusinersen (12‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nusinersen (12‐mg scaled equivalent dose)
Study: 34489756
Drug: LIFEwithIBD intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LIFEwithIBD intervention + Treatment As Usual (TAU)
Study: 32266682
Drug: Canine assisted
Normalized name: CanineAid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canine assisted occupational therapy (n=11)
Study: 32266682
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy sessions as usual (waitlist control group, n=11)
Study: 35483209
Drug: ALIMFUS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALIMFUS therapy for 10 minutes on alternate days for 90 days
Study: 35483209
Drug: ALIMFUS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALIMFUS therapy
Study: 35922010
Drug: Closed Treatment
Normalized name: Closed Pouch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed Treatment (CT)
Study: 35381064
Drug: Cisplatin at
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin at optimal dose of 160 mg/m2 during concurrent phase
Study: 35381064
Drug: Cisplatin at
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin at optimal dose of 260 mg/m2 during induction/adjuvant phase
Study: 35381064
Drug: Cisplatin throughout
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin throughout treatment (no replacement by carboplatin)
Study: 35641012
Drug: Behaviour change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour change physiotherapy intervention (6, 30 min weekly group-based exercise sessions preceded by a 30 min cognitive behaviour discussion group)
Study: 35641012
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (6, 30 min weekly group-based exercise sessions)
Study: 33093457
Drug: IRE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRE plus allogeneic γδ T-cell infusion (Group A)
Study: 33093457
Drug: IRE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRE plus allogeneic γδ T-cell infusion (multiple courses)
Study: 33093457
Drug: IRE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRE plus allogeneic γδ T-cell infusion (single course)
Study: 33297719
Drug: Ulipristal Acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal Acetate (UPA) 5 mg/day
Study: 32583431
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A (twice weekly bortezomib in one six-week cycle followed by eight five-week cycles of four times once weekly bortezomib with melphalan and prednisolone on days 1–4)
Study: 32583431
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (nine four-week cycles of three times once weekly bortezomib with melphalan and prednisolone on days 1–4)
Study: 34146100
Drug: RSVPreF3 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVPreF3 vaccine (30/60/120 µg)
Study: 33239409
Drug: Esaxerenone (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esaxerenone (1.25 mg/d titrated to 2.5 mg/d)
Study: 32521250
Drug: TS-121 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-121 10 mg
Study: 32521250
Drug: TS-121 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-121 50 mg
Study: 32014520
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg followed by misoprostol 800 mcg buccally
Study: 33203692
Drug: Genetic variants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic variants in the retinoic acid receptor alpha (RARA) gene
Study: 33687734
Drug: Tongue cleaning
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongue cleaning with routine oral care
Study: 33687734
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral care alone (Control)
Study: 33118727
Drug: Bretschneider's HTK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bretschneider's HTK solution
Study: 32527261
Drug: PopART standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: PopART standard of care door‐to‐door HTS plus oral HIVST (33 clusters)
Study: 33215948
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication for acute BP
Study: 33127947
Drug: L. reuteri
Normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. reuteri oil drops and ω‐3 PUFA capsules
Study: 33127947
Drug: L. reuteri
Normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. reuteri and placebo regarding ω‐3 PUFA
Study: 33127947
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules and placebo oil drops
Study: 34438047
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (BFB + TDCS)
Study: 35429046
Drug: Expert-match treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expert-match treatment
Study: 35429046
Drug: Self-matching treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-matching treatment
Study: 32730977
Drug: Bumetanide (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (1.0 mg twice daily for 91 days)
Study: 32236116
Drug: One prandial
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One prandial insulin injection before breakfast or main meal with rapid-acting insulin
Study: 32236116
Drug: One prandial
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One prandial insulin injection
Study: 32250463
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg twice daily (Day 8) and once daily (Days 9–16) with a single oral 2.5 mg dose of esaxerenone
Study: 32250463
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg once daily (Days 8–16) with a single oral 5 mg dose of esaxerenone
Study: 33378776
Drug: Conventional colostomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional colostomy (CC)
Study: 33337397
Drug: Conventional Physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Physiotherapy (40 minutes twice a day, 5 times a week for 4 weeks)
Study: 33616561
Drug: Two-implant mandibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-implant mandibular overdentures (IODs)
Study: 34515552
Drug: Individualized oral
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized oral health education (OHE) via a behavioral and educational counseling approach
Study: 32068603
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of conbercept (IVC) 7 days before vitrectomy (group A)
Study: 32068603
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of conbercept (IVC) 14 days before vitrectomy (group B)
Study: 32068603
Drug: No intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravitreal injection of conbercept (non-IVC, group C)
Study: 35878047
Drug: Computerized Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized Cognitive Rehabilitation Therapy (CCRT) - 24 biweekly 90-min sessions
Study: 32471973
Drug: Aprepitant (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125 mg on the 1st day and 80 mg during the following days)
Study: 36066520
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention including educational outreach, computerized clinical decision support on contrast volume and hemodynamic‐guided intravenous fluid targets, and audit and feedback.
Study: 34600060
Drug: API tablets
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: API tablets at low and high compression
Study: 34600060
Drug: API tablets
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: API tablets
Study: 32413174
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (CST)
Study: 37060024
Drug: Angiotensin-receptor blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-receptor blockers (ARBs)
Study: 33662995
Drug: Homeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic treatment for 6 months
Study: 33662995
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no homeopathic treatment)
Study: 35568571
Drug: 3-session motivational
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-session motivational enhancement therapy (MET)
Study: 35568571
Drug: 8-session social
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-session social behaviour and network therapy (SBNT)
Study: 33832806
Drug: Bilateral erector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral erector spinae plane block with 20 mL per side of 0.25% levobupivacaine (group E)
Study: 33832806
Drug: Sham block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham block with 20 mL of normal saline (group C)
Study: 34360267
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention consisting of education and feedback on reducing benzodiazepine prescriptions
Study: 32442746
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (MT) during the immobilisation period, in addition to conventional physiotherapy.
Study: 36416166
Drug: Pedometer-based walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pedometer-based walking program plus TheraBand resistance exercise (7,500 steps/day for 5 days/week, resistance exercise twice a week)
Study: 36416166
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine daily activities)
Study: 33347597
Drug: IUI‐CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: IUI‐CC
Study: 33603385
Drug: Digital medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital medicine system (DMS)
Study: 34924999
Drug: Nalbuphine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.15 mg/kg combined with propofol
Study: 34924999
Drug: Nalbuphine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.2 mg/kg combined with propofol
Study: 33485959
Drug: BDP/FF/G (beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF/G (beclomethasone dipropionate, formoterol fumarate, glycopyrronium)
Study: 35773027
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (FC) 4 g
Study: 33710111
Drug: Prolonged prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged prophylactic systemic antibiotics (PPSA) administered for the duration of the drain